Evidence map›Paper›PMID 42170286›Full record

ArticleTranslational lung cancer research2026

TROP2 expression as a prognostic predictor for osimertinib in patients with

Naohito Hashimoto, Kyoichi Kaira, Hisao Imai, Shota Takei, Kosuke Hashimoto, Ou Yamaguchi, Atsuto Mouri, Mei Hamada, Taku Honma, Hiroshi Kagamu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Naohito HashimotoDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Kyoichi KairaDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Hisao ImaiDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Shota TakeiDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Kosuke HashimotoDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Ou YamaguchiDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Atsuto MouriDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Mei HamadaDepartment of Diagnostic Pathology, Saitama Medical University, Saitama, Japan.
Taku HonmaDepartment of Diagnostic Pathology, International Medical Center, Saitama Medical University, Saitama, Japan.
Hiroshi KagamuDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Osimertinib is the standard first-line treatment for epidermal growth factor receptor ( Methods: We retrospectively analyzed 155 patients with recurrent or metastatic Results: TROP2 overexpression was observed in 72 patients (46.5%). While TROP2 overexpression was not independently associated with PFS, it was associated with shorter OS in the overall cohort. In multivariate analysis, age, performance status, clinical stage, liver metastasis, and TROP2 overexpression were identified as independent prognostic factors for OS. Subgroup analysis showed that TROP2 overexpression was associated with worse OS in patients with Conclusions: TROP2 overexpression is an independent predictor of poor OS in patients with

Indexed as

epidermal growth factor receptor mutation (EGFR mutation)lung cancerosimertinibprognosisTrophoblast cell-surface antigen 2 (TROP2)

Identifiers

PMID42170286
PMCPMC13186682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.